Abstract |
Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].
|
Authors | J B Furness |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 2
Issue 10
Pg. 1437-40
(Oct 2001)
ISSN: 1472-4472 [Print] England |
PMID | 11890361
(Publication Type: Journal Article, Review)
|
Chemical References |
- Naphthyridines
- Neurokinin-1 Receptor Antagonists
- TAK 637
|
Topics |
- Animals
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Colonic Diseases, Functional
(drug therapy)
- Depression
(drug therapy)
- Humans
- Naphthyridines
(pharmacology, therapeutic use)
- Neurokinin-1 Receptor Antagonists
- Structure-Activity Relationship
- Urinary Incontinence
(drug therapy)
|